Bovril and moclobemide: a novel therapeutic strategy for central autonomic failure
1994; Elsevier BV; Volume: 344; Issue: 8932 Linguagem: Inglês
10.1016/s0140-6736(94)90752-8
ISSN1474-547X
AutoresFiona E. Karet, J. E. Claire Dickerson, Jerry M. Brown, Morris J. Brown,
Tópico(s)Pain Mechanisms and Treatments
ResumoThe consumption of tyramine-containing foods is contraindicated in patients on classic monoamine oxidase (MAO) inhibitors. We report successful therapeutic use of moclobemide (a MAO-A selective inhibitor) plus controlled amounts of Bovril (a tyramine-rich yeast-extract available as a food) in a patient with pure central autonomic failure who was rendered bed-bound by severe postural hypotension. Standing blood pressure is now at least 90/45 mm Hg. The selectivity of moclobemide allows about a tenth of ingested tyramine to reach nerve endings and thus the modest hypertensive effect of this combination re-established day-to-day function by restoring normotension.
Referência(s)